Seattle Genetics preps for busy fall

Dealmaking machine Seattle Genetics is expecting a busy fall, says Seeking Alpha. Between September and October, the drug developer will recieve results from up to three clinical trials, two of which cover the company's flagship drug SGN-35 (brentuximab vedotin). The drug, which has been fast-tracked by the FDA, is in Phase III testing for Hodgkin's lymphoma and anaplastic large cell lymphoma. A Phase I study is also under way that is testing whether SGN-35 can be used for Hodgkin's lymphoma patients who haven't responded to first-line therapy. Earlier this year Takeda's Millennium plunked down $60 million upfront and promised up to $230 million in milestones and $75 million in research funds for a commercialization deal covering SGN-35.

Seattle Genetics has a raft of other trials in progress. In addition to early-stage trials of SGN-35 for other indications, the company is conducting Phase II trials of SGN-33 (lintuzumab) for acute myeloid leukemia and myelodysplastic syndromes. Genentech canceled its $860 million pact for dacetuzumab after seeing lackluster results in a broad range of Phase I trials. But Seeking Alpha notes that the addition of a drug conjugate could help revive the drug.

- read the report from Seeking Alpha

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.